Smartphone-based support systems offer unique advantages in medication adherence and behavioral change
Similar content being viewed by others Introduction Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have revolutionized the treatment landscape for type 2 diabetes mellitus (T2DM) and obesity, offering significant benefits in glycemic control, weight reduction, and cardiometabolic protection
By boosting Treg activity, TA1 may help restore the immune tolerance that MS disrupts, potentially reducing relapse frequency without the broad immunosuppression caused by conventional DMTs
A patient who has developed gastroparesis or another severe injury after using a GLP-1 drug may face immense personal and financial burdens
Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
But occasionally, they can be a sign of something more serious like thyroid disorders, diabetes or certain cancers
